What are the drug interactions of Revumenib (Revuforj)?

Revumenib (trade name: Revuforj) is an oral, first-in-class targeted Menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with KMT2A gene rearrangement or NPM1 mutation.

What are the drug interactions of Revumenib (Revuforj)?

You should always inform your doctor of any prescription or over-the-counter medicines, vitamins/minerals, herbal products and other supplements you are taking.

In particular, before taking Revumenib, be sure to discuss with your doctor if you are using any of the following medicines:

Itraconazole, Posaconazole or Voriconazole, which are antifungal medications.

Cobicistat, a medication used for the treatment of HIV infection.

Rifampicin, a commonly used medication for the treatment of tuberculosis infection.

St. John's Wort, a supplement that may be used for the treatment of depression.

Medications that may cause QT interval prolongation (a potentially dangerous heart rhythm disorder).

Many other medicines may alter the blood concentration of Revumenib, and vice versa. Inform your doctor of all medicines you are taking or have recently taken.

This may not be a complete list of all possible drug interactions with Revumenib. Be sure to consult your doctor.

Warnings and Precautions for Revumenib (Revuforj)

Important information to know before preparing to disperse Revumenib tablets in water:

The method of dispersing Revumenib tablets in water for oral administration is intended only for patients who cannot swallow the tablets whole. Patients who can swallow the tablets whole should not cut, chew or disperse the tablets in water.

Take (or administer) Revumenib exactly as directed by your doctor. Do not change the dose or stop taking Revumenib unless instructed to do so by your healthcare provider.

Monitoring Guidelines Before and During Treatment with Revumenib (Revuforj)

Reduce the white blood cell count to below 25 Gi/L before initiating Revumenib treatment.

Assess blood cell counts, electrolytes and liver enzymes prior to the start of Revumenib and monthly thereafter.

Perform an electrocardiogram (ECG) before the initiation of Revumenib, at least once weekly for the first 4 weeks, and at least once monthly thereafter.